More than half of people with atypical hemolytic uremic syndrome (aHUS) in India have self-reactive antibodies targeting complement factor H (CFH), a protein that regulates the activity of the complement system, according to a recent study. These patients generally had better outcomes, being less likely to develop end-stage…
News
A woman in Italy developed atypical hemolytic uremic syndrome (aHUS) as a result of a blood cancer, which resolved after the cancer was brought into remission, a case study shows. The report, “Marginal zone lymphoma with anti-factor H IgM and atypical hemolytic uremic syndrome successfully treated…
A 47-year-old man developed atypical hemolytic uremic syndrome (aHUS) after using cocaine, but ultimately recovered before his condition led to long-term kidney damage, according to a case report in Spain. While past reports have linked aHUS to cocaine use, such cases are uncommon. The man described in the report…
Inflammation of the pancreas, known as pancreatitis, can occur alongside the rare disease atypical hemolytic uremic syndrome (aHUS) — as a team of researchers from China highlighted in a new report outlining the case of a young woman found to have both conditions. The woman sought medical attention due…
Soliris (eculizumab) helped control atypical hemolytic uremic syndrome (aHUS) in a patient whose symptoms included seizures and signs of neurological damage, according to a case report. The researchers said the case points to “the importance of timely diagnosis and treatment of aHUS as well as the…
Soliris (eculizumab) is safe and effective for treating children with various types of hemolytic uremic syndrome (HUS), including atypical HUS (aHUS), according to a real-world study involving pediatric patients in Israel. In fact, more than half of the children with aHUS given Soliris in the study achieved a…
Plasma exchange therapy successfully managed atypical hemolytic uremic syndrome (aHUS) triggered by pancreas inflammation in a 72-year-old man, according to a case report from China. However, discontinuation of plasma exchange and a transition to hemodialysis — a treatment used to remove waste and excessive fluid from the blood when…
Plasma exchange therapy followed by treatment with Soliris (eculizumab) was effective at managing atypical hemolytic uremic syndrome (aHUS) in a boy in China. The case was described in the report, “Plasma exchange combined with eculizumab in the management of atypical hemolytic uremic in pediatric patients:…
Epysqli (eculizumab-aagh), a biosimilar of Soliris (eculizumab), is now available for patients in the U.S., according to an announcement from Samsung Bioepis and Teva Pharmaceuticals. The biosimilar is authorized to treat people with atypical hemolytic uremic syndrome (aHUS), as well as paroxysmal nocturnal hemoglobinuria, and…
A woman with lupus in her early 30s, who developed atypical hemolytic uremic syndrome (aHUS) after pregnancy, was not suspected of having the rare condition until five days after her baby’s birth, which resulted in her not receiving the correct treatment, according to a case report from researchers in…
Recent Posts
- Study finds alternative pathway is main driver of aHUS
- Rapid, sustained aHUS response seen with Ultomiris in real-world data
- Team care saves mother with trio of postpartum complications
- Once a good side hustle, donating plasma is now too risky for me
- Treatment halts aHUS recurrence after COVID-triggered relapse
- For women like me, hair loss can be particularly devastating
- aHUS drugs restore kidney function in 60% of patients in Romania
- aHUS has changed my life in drastic and unexpected ways
- Rare lupus nephritis–aHUS case improves after Soliris treatment
- How my young children had to adapt to having a sick parent